EZH2 and diffuse large B-cell lymphoma: EZH2 is a promising therapeutic target for DLBCL treatment, as several studies involving EZH2 mutated DLBCL cells have shown that small molecule inhibitors targeting EZH2 could induce apoptosis and cell cycle arrest [68,69].